spacer
home > ebr > current issue
PUBLICATIONS

European Biopharmaceutical Review

ebr
Winter 2015

   
Text
PDF
Editor’s Letter

In light of the Ebola outbreak, Deborah O’Neil reminds us just what our industry is capable of, as well as reflecting on a number of this edition’s features.
 
view
download pdf
bullet
BioResearch and Innovation
Human Airway Epithelium

Hold Your Breath


Air-liquid interface culture models can provide a powerful platform in preclinical drug development for various respiratory diseases. Samuel Constant, Song Huang and Ludovic Wiszniewski at Epithelix and Christophe Mas at OncoTheis explore further.
 
view
download pdf
bullet
Discovery Technology
Fluorinated Pharmaceuticals

Synthesis and Opportunity


As fluorinated active pharmaceutical ingredients continue to be introduced into the marketplace, Graham Sandford at Durham University and Cormac Murphy at University College Dublin examine the technology.
 
view
download pdf
BioDiscovery
Molecular Biomarkers

Mental Change


Efforts in the field of mental illness could lead to novel therapeutic targets and the individualisation of patient strategies. Paul C Guest at Cambridge University reflects on how considering schizophrenia as a whole body disease may result in better treatment approaches.
 
view
download pdf
bullet
Biodevelopment and Manufacturing
Biomanufacturing Strategies

Keep it Flexible


Accinov’s Sylvain Peyrache and Agnes Nagy contemplate the effect biologics are having on the biopharmaceutical industry. With the recent progression of technology, new solutions are allowing companies to implement biomanufacturing strategies far more easily according to regulation requirements and project timelines.
 
view
download pdf
Cell-Based Therapeutics

Heading For Market


Stefanos Theoharis
from apceth GmbH maintains that it is imperative to keep in mind the various end-goals when developing cell-based therapeutics. This will position the final product well in the marketplace of tomorrow, and deliver real benefit to patients in need.
 
view
download pdf
Biopharmaceutical Manufacturing

Synthetic Biology


Dominik Schelshorn, Sanda Ljubicic, Imre Berger and Daniel Fitzgerald of Geneva Biotech contemplate the new era of synthetic biology, and how the rapid advance of tools and technologies is changing the way we produce biopharmaceuticals.
 
view
download pdf
bullet
THERAPEUTICS FOCUS - VACCINES AND INFECTIOUS DISEASES
Case Study: Schistosomiasis

Positive Action


Schistosomiasis is one of the most prevalent – yet often neglected – parasitic diseases. Elly Kourany-Lefoll, Jennifer Keiser and Remco de Vrueh at the Pediatric Praziquantel Consortium explain how a recent collaboration hopes to formulate readily administrable treatments.


 
view
download pdf
Q&A: Vaccine Insight

Developing Immunity


Frost & Sullivan’s Aish Vivekanandan guides EBR through the hurdles of vaccine development and the impact of Ebola, before discussing what we can expect from the next decade of research.
 
view
download pdf
bullet
CANCER FOCUS
Active Immunotherapy

Fighting Fit


Research has shown the potential for targeted immunotherapy in non-infectious diseases, specifi cally in the prevention and management of non-small-cell lung cancer. Bioven’s Erik D’Hondt and Pangaea Biotech’s Jordi Bertran-Alamillo and Jordi Codony-Servat comment on recent clinical trial results.
 
view
download pdf
Radioimmunotherapy

Alpha, Better


Treating cancer is not a one-size-fits-all proposition. Kaushik Dave and Dragan Cicic from Actinium Pharmaceuticals Inc run through the latest developments in radioimmunotherapy and the promising effects of alpha-emitters in reducing cancerous cells.
 
view
download pdf
Oncology Studies

Put to the Test


SMS-oncology’s Lindy Bosch and Raymond Hoffmans look at the components typically comprising a Phase 1 oncology study, describing characteristics such as sponsor types, drugs used, dose levels and patient stratification, as well as overall trial objectives.
 
view
download pdf
bullet
REVIEWS AND PREVIEWS
Event Review: Crystallography

Crystal Clear


Following on from 2014 – the Year of Crystallography –EBR’s Emma Naks reviews photographer Max Alexander’s exhibition, Illuminating Atoms, which captured crystallography experiments in action, as well as displaying portraits of modern day crystallographers
 
view
download pdf
bullet
INDUSTRY DYNAMICS
Funding Models

Destination Europe


Poul Sørensen and Emil Pot of European Biopharmaceutical Enterprises comment on Europe’s sluggish R&D output, and recommend mobilising investment to encourage innovative entrepreneurship as a means of boosting economic growth.
 
view
download pdf
In Brief

Crouching Tiger


Emile Bellott casts his mind east and asks: will China have multinational pharma companies of its own? And how will they compare to those in Europe and America?
 
view
download pdf
bullet
INTELLECTUAL PROPERTY AND TECH-TRANSFER
Intellectual Property Act

Right of Way


Jasnoop Cheema at Greenaway Scott assesses the UK’s Intellectual Property Act, outlining how the latest changes hope to simplify the current patenting process and encourage growth in the life sciences sector.
 
view
download pdf
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

News and Press Releases

Code-N to Provide Secure, Cloud-Based Scientific Intelligence to BioPharma Companies via Exostar’s Life Sciences Identity Hub

HERNDON, VA, and MENLO PARK, CA, February 18, 2015 – Exostar, an innovative information technology company offering cloud-based solutions that enable secure, cost-effective business-to-business collaboration, and Code-N today announced that Code-N will connect its cloud-based solutions to Exostar’s Life Sciences Identity Hub.  By joining Exostar’s partner program as an Application Partner, Code-N ensures its Competitive Profiler, Drug Repurposing, and Safety solutions can be securely accessed by organizations and individuals who are members of Exostar’s rapidly expanding life science and healthcare community.
More info >>

White Papers

Overcoming research challenges with Adaptive Trials

Packaging Coordinators, Inc.

There has been cause for concern within the pharmaceutical industry over the last five years, regarding increasing research and development costs, combined with a fall in the number of new drugs brought to market. In an attempt to overcome this issue there has been a significant rise in the use of adaptive clinical trial designs, whilst saving time and money as well as facilitating more effective decision making. One of the biggest challenges that pharmaceutical companies have experienced has been delivering compliant clinical trials supplies across diverse patient populations in the relatively short timeframes that adaptive trial designs require, remaining focused on ensuring that patient compliance and product quality is in no way compromised. This demand has led to the launch of fast response services that support Research and Development in responding to changing dosing regimens mid-trial.
More info >>

Industry Events

Exploratory Clinical Development World Europe

2-3 June 2015, Bishopsgate, London, UK

Exploratory Clinical Development World Europe is recognised as the premier conference for understanding the right strategies and methods to assess safety & efficacy and make timely go/no go decisions.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement